513 Trial in progress: phase 1 first-in-human study of XL092 administered alone or in combination with immune checkpoint inhibitors in patients with inoperable locally advanced or metastatic solid tumors

Background XL092 is a novel oral multi-targeted inhibitor of receptor tyrosine kinases. In preclinical studies, oral dosing with XL092 resulted in pharmacodynamic inhibition of MET, TAM kinases (AXL, MER), and VEGFR2 phosphorylation and was associated with significant anti-tumor activity in xenograft tumor models. Drugs targeting TAM kinases may promote an immune-permissive environment, which may enhance response to immune checkpoint inhibitors...